EP 3212290 A4 20190123 - SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Title (en)
SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Title (de)
SERPINFUSIONSPOLYPEPTIDE UND VERFAHREN ZUR VERWENDUNG DAVON
Title (fr)
POLYPEPTIDES DE FUSION DE SERPINE ET LEURS PROCÉDÉS D'UTILISATION
Publication
Application
Priority
- US 201414524832 A 20141027
- US 2015057533 W 20151027
Abstract (en)
[origin: WO2016069574A1] This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
IPC 8 full level
A61P 37/00 (2006.01); C07K 14/81 (2006.01); C07K 16/00 (2006.01); C07K 16/24 (2006.01)
CPC (source: EP IL KR RU)
A61K 38/55 (2013.01 - IL); A61P 1/04 (2018.01 - EP); A61P 3/10 (2018.01 - EP); A61P 7/00 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 11/00 (2018.01 - EP); A61P 11/06 (2018.01 - EP); A61P 17/02 (2018.01 - EP); A61P 17/06 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 29/00 (2018.01 - EP KR); A61P 31/00 (2018.01 - EP KR); A61P 31/04 (2018.01 - EP); A61P 31/10 (2018.01 - EP); A61P 31/12 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 37/00 (2018.01 - EP); A61P 37/02 (2018.01 - EP); A61P 37/06 (2018.01 - EP); C07K 14/7155 (2013.01 - RU); C07K 14/8121 (2013.01 - EP IL KR RU); C07K 16/241 (2013.01 - EP KR RU); C07K 19/00 (2013.01 - IL RU); A61K 38/00 (2013.01 - KR); C07K 2317/21 (2013.01 - EP IL KR); C07K 2317/52 (2013.01 - EP IL KR); C07K 2317/76 (2013.01 - EP IL KR); C07K 2319/00 (2013.01 - EP); C07K 2319/30 (2013.01 - EP IL KR); C07K 2319/31 (2013.01 - EP IL KR); C07K 2319/70 (2013.01 - EP IL KR)
Citation (search report)
- [IY] WO 2013003641 A2 20130103 - INHIBRX LLC [US], et al
- [Y] US 2013058919 A1 20130307 - LAZAR GREGORY ALAN [US], et al
- [Y] WO 2014001325 A1 20140103 - HOFFMANN LA ROCHE [CH], et al
- [I] WO 2004092219 A2 20041028 - PROTEIN DESIGN LABS INC [US], et al
- See also references of WO 2016069574A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2016069574 A1 20160506; AU 2015339507 A1 20170511; AU 2015339507 B2 20210701; AU 2021240153 A1 20211028; BR 112017008525 A2 20180130; CA 2965151 A1 20160506; CN 107206257 A 20170926; CN 114316068 A 20220412; EP 3212290 A1 20170906; EP 3212290 A4 20190123; HK 1244460 A1 20180810; IL 251799 A0 20170629; IL 251799 B1 20231201; IL 251799 B2 20240401; IL 308589 A 20240101; JP 2017537888 A 20171221; JP 2020180157 A 20201105; JP 6737781 B2 20200812; KR 20170091096 A 20170808; KR 20240005109 A 20240111; MX 2017005467 A 20171130; MX 2021012047 A 20211103; RU 2017118325 A 20181129; RU 2017118325 A3 20190321; RU 2746550 C2 20210415; SG 10201903142R A 20190530; SG 11201703390S A 20170530; UA 127305 C2 20230719
DOCDB simple family (application)
US 2015057533 W 20151027; AU 2015339507 A 20151027; AU 2021240153 A 20210928; BR 112017008525 A 20151027; CA 2965151 A 20151027; CN 201580071331 A 20151027; CN 202111439584 A 20151027; EP 15854670 A 20151027; HK 18103148 A 20180305; IL 25179917 A 20170419; IL 30858923 A 20231115; JP 2017522654 A 20151027; JP 2020121953 A 20200716; KR 20177014414 A 20151027; KR 20237043666 A 20151027; MX 2017005467 A 20151027; MX 2021012047 A 20170426; RU 2017118325 A 20151027; SG 10201903142R A 20151027; SG 11201703390S A 20151027; UA A201705128 A 20151027